Meeting Description

The National Cancer Institute (NCI) Breast Cancer Steering Committee (BCSC) convened a Clinical Trial Planning Meeting (CTPM) for Omitting Surgery in Patients with Complete Clinical/Radiologic Response to Neoadjuvant Chemotherapy on October 16-17, 2017 in Rockville, MD. The goal of the meeting was to develop design recommendations for a feasible clinical trial to determine if surgery can be omitted for a subset of breast cancer patients who have a complete clinical/radiologic response to neoadjuvant chemotherapy. The meeting attendees included BCSC members, members of the BCSC Breast Oncology Local Disease (BOLD) Task Force, breast cancer clinicians (medical oncologists, surgical oncologists, and radiation oncologist), radiologists, biostatisticians, patient advocates, and NCI staff.

Background

Certain subtypes of breast cancer patients (triple negative and HER2 positive) have high rates of pathologic complete response (pCR) to neoadjuvant systemic therapy1. Patients treated with neoadjuvant chemotherapy who achieve a pCR have very low rate of local recurrence and excellent overall survival, leading to interest in the concept of eliminating surgery in these patients. Prior studies2, 3, 4 have suggested that it may be feasible to omit surgery, but were not performed using current systemic therapy regimens or imaging techniques. In order for surgery to be safely omitted, there is a need to be able to identify patients that have a high likelihood of achieving a pCR, and therefore a low risk of recurrence. Prior studies have shown clinical exam to have poor predictive value for prediction of pCR. In TBCRC 017, the overall negative predictive value (NPV) of a negative breast MRI was 47%;5 NPV improves to 80-87% when multiple imaging modalities are utilized, but this is still not likely sufficient to allow for omission of surgical excision.

Two more recent studies have assessed whether biopsy of the tumor bed can improve prediction of pCR in patients who have received neoadjuvant systemic therapy6,7 and results suggest that a biopsy may improve predictive accuracy, but identification of the tumor bed is necessary for sufficient negative predict value.

Two current studies, NRG BR0058 and TBCRC 0409, will further inform the design of a definitive clinical trial of surgery omission in women treated with neoadjuvant systemic therapy. NRG BR005 is assessing whether the combination of a negative tumor bed biopsy and negative trimodality imaging (mammogram, ultrasound and MRI) is sufficiently accurate to predict whether a patient will have a CR. TBCRC 040 is assessing the role of ctDNA in predicting pCR. The current studies and prior data set the stage for a trial that will definitively determine whether it is safe to omit surgery in patients who are...
predicted to have a high probability of pCR. This study could allow for a paradigm shift in the treatment of patients with a good response to neoadjuvant treatment.

Consensus & Recommendations

A clinical trial should be designed to definitively determine whether it is safe to omit surgery in patients who are predicted to have a high probability of pCR. The consensus was for the study to be either a randomized non-inferiority design or a hybrid design in which the lowest risk patients (small, N0 tumors with clinical CR) do not receive surgery and are followed for outcomes and higher risk patients are randomized to receive surgery or not receive surgery. The trial should include TNBC and HER2+ patients. Results from NRG BR005 will inform certain aspects of the next trial, including:

- Are false negative rates different in different biologic subtypes of breast cancer?
- Is trimodality imaging necessary for accurate prediction of pCR?
- How do imaging results from the breast reflect what is happening in the axilla?
- What issues affect physician and patient acceptability?

This Executive Summary presents the consensus arising from the Clinical Trial Planning Meeting. These recommendations are not meant to address all clinical contexts, but rather represent priorities for publicly funded clinical research.

Anticipated Actions

A Working Group consisting of representatives from each of the NCTN Groups, biostatisticians, patient advocates, and subject matter experts will be formed to write a manuscript and design the clinical trial.

References

AGENDA
NCI Breast Cancer Steering Committee (BCSC) Clinical Trial Planning Meeting (CTPM)
Omitting Surgery in Patients with Complete Clinical/Radiologic Response to Neoadjuvant Chemotherapy: A Paradigm Shift
October 16-17, 2017

NCI Shady Grove Building
9609 Medical Center Drive
Rockville, Maryland 20850
Meeting Room: Seminar 406, Terrace Level

MONDAY, OCTOBER 16

1:00 pm Welcome and meeting objectives Tom Julian and Alastair Thompson

Review of prior and current studies

1:15 pm Background Alastair Thompson
1:35 pm NRG BR005 Tom Julian
1:55 pm TBCRC 040 Ben Park
2:15 pm Discussion

Current Landscape and Setting the Stage

2:30 pm Study population, eligibility considerations Eric Winer
2:50 pm Discussion

3:00 pm Imaging Jennifer De Los Santos
3:20 pm Discussion

3:30 pm Pathology/cytology assessment Savitri Krishnamurthy
3:50 pm Discussion

4:00 pm BREAK

4:15 pm Surgical Management Mark Basik
4:35 pm Discussion

4:45 pm Radiation Treatment Without Surgery Julia White
5:05 pm Discussion
**Trial Design**

5:20 pm  Trial Design  
*Moderators: Lisa McShane, Shelley Hwang, Bill Barlow, Chuck Geyer, Jamie Wagner*

6:50 pm  Summary of day 1 and preparation for day 2  
*Tom Julian, Alastair Thompson*

7:00 pm  Adjourn

**TUESDAY, OCTOBER 17**

7:00 am  Welcome, overview of day 2 and charge  
*Tom Julian, Alastair Thompson*

7:10 am  Imaging: Working Session  
*Moderators: Connie Lehman, Heidi Umphrey*

8:40 am  Surgical Management: Working Session  
*Moderators: Marilyn Leitch, Terry Mamounas, Julia Tchou*

10:10 am  BREAK

10:20 am  Radiation Treatment Without Surgery: Working Session  
*Moderators: Reshma Jagsi, Tim Whelan, Rich Zellars*

11:50 am  LUNCH (on your own)

12:30 pm  BREAKOUT SESSIONS

<table>
<thead>
<tr>
<th>Study population/eligibility:</th>
<th>Biomarkers</th>
<th>QOL/PROs</th>
</tr>
</thead>
</table>
| Room: Seminar 406, Terrace Level  
*Moderators: Lisa Carey, Gabe Hortobagyi* | Room: Seminar 110, Terrace Level  
*Moderators: Peggy Porter, Fraser Symmans, Antonio Wolff* | Room: 2E908 (2nd floor)  
*Moderators: Liz Frank, Lynn Henry, Susie McCloskey* |

1:40 pm  BREAK/Return to Meeting Room: Seminar 406, Terrace Level

Breakout Session Report Outs and Discussion

1:55 pm  Study population/eligibility:  
*Lisa Carey, Gabe Hortobagyi*

2:15 pm  QOL/PROs  
*Liz Frank, Lynn Henry, Susie McCloskey*

2:35 pm  Biomarkers  
*Peggy Porter, Fraser Symmans, Antonio Wolff*
Practical issues

2:55 pm  Patient & physician acceptability  
Jane Perlmutter, Reshma Jagsi

3:15 pm  Timeline, Funding, “Ownership”  
Larissa Korde

3:45 pm  Summary and consensus on trial design elements, action items  
Tom Julian, Alastair Thompson

4:00 pm  ADJOURN
PARTICIPANT LIST

Jeffrey Abrams, MD
Associate Director
Cancer Therapy Evaluation Program
National Cancer Institute

Stewart Anderson, PhD, MA
Professor and Statistician
University of Pittsburgh
NRG Oncology

William Barlow, PhD
Statistician
SWOG/Cancer Research & Biostatistics

Mark Basik, MD
Surgical Oncologist
Jewish General Hospital

Judy Boughey, MD
Professor of Surgery
Mayo Clinic

Lynn Butler, MS
NCI Breast Cancer Steering Committee Program Coordinator
The EMMES Corporation

Lisa Carey, MD
Distinguished Professor
University of North Carolina Lineberger Comprehensive Cancer Center

Coleen Crespo, BS, MIS
Clinical Data Specialist III
Duke Clinical Research Institute
Patient Advocate

Jennifer De Los Santos, MD
Professor
University of Alabama at Birmingham

Jared Foster, PhD
Mathematical Statistician
Biostatistics Branch
National Cancer Institute

Liz Frank, MA
Patient Advocate
Dana-Farber Cancer Institute

Charles Geyer, MD
Associate Director
Clinical Trials Office
Virginia Commonwealth University
Massey Cancer Center

Lyndsay Harris, MD
Acting Associate Director
Cancer Diagnosis Program
National Cancer Institute

Jennifer Hayes, PhD
Program Director
Breast Cancer Steering Committee
Coordinating Center for Clinical Trials
National Cancer Institute
Toby Hecht, PhD  
Deputy Division Director  
Translational Research Program  
National Cancer Institute

Norah Lynn Henry, MD, PhD  
Associate Professor  
University of Utah

Gabriel Hortobagyi, MD  
Professor  
The University of Texas MD Anderson Cancer Center

Shelley Hwang, MD, MPH  
Professor of Surgery and Chief of Breast Surgical Oncology  
Duke University School of Medicine

Deborah Jaffe, PhD  
Program Director  
Coordinating Center for Clinical Trials  
National Cancer Institute

Reshma Jagsi, MD, Dphil  
Physician  
University of Michigan Medical School

Thomas Julian, MD  
Director, Breast Surgical Oncology  
Allegheny Health Network  
Deputy Chair, NRG Oncology

Larissa Korde, MD  
Head, Breast Cancer Therapeutics  
Cancer Therapy Evaluation Program  
Clinical Investigations Branch  
National Cancer Institute

Savitri Krishnamurthy, MD  
Professor and Deputy Division Head  
The University of Texas MD Anderson Cancer Center

Constance Lehman, MD, PhD  
Director of Breast Imaging and Professor of Radiology  
Harvard Medical School  
Massachusetts General Hospital

A. Marilyn Leitch, MD  
Physician and Associate Professor  
UT Southwestern Medical Center

Eleftherios Mamounas, MD  
Medical Director  
Comprehensive Breast Program  
Orlando Health UF Health Cancer Center

Shahla Masood, MD  
Professor and Chair  
Department of Pathology  
University of Florida

Worta McCaskill-Stevens, MD  
Chief  
Community Oncology and Prevention Trials Research Group  
National Cancer Institute

Susie McCloskey, MD  
Assistant Professor  
Radiation Oncology  
University of California, Los Angeles

Lisa McShane, PhD  
Acting Associate Director  
Biometric Research Program  
National Cancer Institute

Meg Mooney, MD  
Chief  
Clinical Investigations Branch  
National Cancer Institute

Ben Park, MD, PhD  
Professor of Oncology  
Johns Hopkins University
Jane Perlmutter, PhD, MBA  
Patient Advocate

JoyAnn Phillips Rohan, PhD  
Program Director  
Translational Research Program  
National Cancer Institute

Peggy Porter, MD  
Professor  
Fred Hutchinson Cancer Research Institute

Sheila Prindiville, MD  
Director  
Coordinating Center for Clinical Trials  
National Cancer Institute

Steven Reeves, PhD  
Program Director  
Coordinating Center for Clinical Trials  
National Cancer Institute

Brian Rodgers, MD  
Medical Officer  
Clinical Trials Branch  
National Cancer Institute

Lalitha Shankar, MD, PhD  
Branch Chief  
Clinical Trials Branch  
National Cancer Institute

W. Fraser Symmans, MD  
Professor  
The University of Texas MD Anderson Cancer Center

Julia Tchou, MD, PhD  
Associate Professor, Breast Surgery  
University of Pennsylvania

Alastair Thompson, MD  
Professor of Surgery  
The University of Texas MD Anderson Cancer Center

Heidi Umphrey, MD  
Breast Radiologist  
Midsouth Imaging

Jamie Wagner, DO  
Division Chief, Breast Surgery  
University of Kansas Health System

Timothy Whelan, BM, BCh  
Professor  
McMaster University

Julia White, MD  
Professor and Vice Chair  
The Ohio State University

Eric Winer, MD  
Director  
Breast Oncology Program  
Dana-Farber Cancer Institute

Antonio Wolff, MD, FACP, FASCO  
Professor of Oncology  
Johns Hopkins University

Richard Zellars, MD  
William A. Mitchell Professor and Chair  
Indiana University School of Medicine